Ar­cutis wins la­bel ex­pan­sion for younger use of pso­ri­a­sis cream Zo­ryve

More than a year af­ter it was ap­proved for adults and chil­dren 12 years and old­er, Ar­cutis Bio­ther­a­peu­tics’ steroid-free top­i­cal cream for plaque pso­ri­a­sis is now avail­able for younger kids.

The FDA has ap­proved Zo­ryve (rof­lu­mi­last) for chil­dren as young as 6, Ar­cutis an­nounced Fri­day. The com­pa­ny test­ed Zo­ryve specif­i­cal­ly in skin folds for this pop­u­la­tion, where pso­ri­a­sis is more like­ly to oc­cur com­pared with adults. Ar­cutis touts the drug as a non-greasy, fast-ab­sorb­ing — and im­por­tant­ly, steroid-free — op­tion for young kids.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER